Sexually transmitted infection (STI) incidence is on the rise in the United States. The increase is especially pronounced in adolescents (15-24 years of age). Despite making up only a quarter of the population, adolescents account for approximately half of new STIs in the United States every year. This review summarizes recent developments in the field of STIs, excluding HIV, in adolescents.
INTRODUCTION
Of approximately 20 million new sexually transmitted infections (STIs) each year in the United States, half of cases occur among adolescents age 15-24 years. It is estimated that one out of four sexually active adolescent women have an STI, most commonly Chlamydia trachomatis (CT) infection and human papillomavirus (HPV) infection (see Table 1 for abbreviations). STI rates in the United States are on the rise, in both men and women, and much of this increase is occurring in adolescents [1] .
Adolescents are uniquely at risk for STIs from both behavioral and biological perspectives. Behaviorally, adolescents are more likely to engage in high-risk sexual behavior such as concurrent partners or sex without a condom [2] . Behavioral disinhibition is due in part to the fact that the prefrontal cortex, responsible for executive function, is still developing throughout adolescence [3] . Furthermore, adolescents are less likely than adults to access and utilize sexual health services [2] . Those factors lead to a higher chance of exposure and a lower chance of diagnosis and treatment.
From a biological perspective, adolescent women are particularly susceptible to STIs like CT and HPV because of lower production of cervical mucous and increased cervical ectopy [2, 4] . Therefore, if exposed to an STI, adolescent women are more likely than adults to get infected.
STIs can cause various health problems if left untreated. Tertiary stage syphilis can lead to nervous system and cardiovascular system damage, and congenital syphilis can cause serious complications or infant death [5] . CT, Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) can cause adverse birth outcomes and infertility [6] [7] [8] . Certain strains of HPV can lead to cervical, oropharyngeal, or rectal cancer [9] . Additionally, STIs have been associated with increased susceptibility to and spread of HIV infection [10] .
Despite the high prevalence and high morbidity, there are relatively limited data on STIs in adolescents. Most studies and guidelines focus on infections and treatment in adults. However, to adequately address the STI epidemic, it is essential to understand and prevent adolescent infections.
The aim of this review is to describe current trends and recommendations regarding STIs, excluding HIV, in adolescent populations. Specific attention is given to populations at increased risk of acquiring an STI, including women and young MSM (YMSM). Future directions of STI screening and prevention are also discussed.
EPIDEMIOLOGY OF SEXUALLY TRANSMITTED INFECTIONS IN ADOLESCENTS
STI rates are increasing among adolescents in the United States. However, infection rates vary by sex, geography, and sexual practices. According to the 2016 STD Surveillance report, CT and NG are more common among adolescents than any other age group. The rate of CT infection among women aged Table 2 and Fig. 1 [2] .
There are less data on the total prevalence of HPV in adolescents. In a study of HPV prevalence from 2009 to 2012, it was estimated that 29.0% of women aged 14-19 years and 58.7% of women aged 20-24 years were infected with HPV [11 && ]. Although there are over 150 strains of HPV, the majority present no symptoms and resolve spontaneously. However, HPV types 6 and 11 account for 90% of genital warts, and HPV types 16 and 18 account for 70% of cervical cancer cases [12, 13] . Prevalence of those four strains specifically was 4.3% among women aged 14-19 years and 12.1% among women aged 20-24 years. Notably, the study found that in 2012, only 6 years after the HPV vaccine introduction in 2006, there was a 64% reduction in HPV 6, 11, 16, and 18 prevalence among women aged 14-19 years, and a 34% reduction among women aged 20-24 years [11 && ]. The data
KEY POINTS
STIs in adolescents are on the rise in the United States, with particularly high rates among young women and MSM.
Barriers to health services and concerns about confidentiality often prevent adolescents from receiving recommended STI screening.
Vaccines, such as the HPV vaccine, represent a powerful and promising way to prevent STIs and associated morbidities.
Research is urgently needed to determine strategies to increase uptake of STI screening among adolescents. suggest high vaccine effectiveness and the importance of continued efforts to increase vaccination coverage. With 2016 HPV vaccination rates in the United States around only 49.5% for women aged 13-17 years and 37.5% for men aged 13-17 years, there is significant opportunity to prevent HPVrelated genital warts and cancers [14] . Additional STIs, such as genital herpes simplex virus (HSV) and TV are also common among adolescents [15, 16] . Neither are reported nationally, making it difficult to assess epidemiologic trends [2] . Several studies have shown that, although HSV-2 typically causes genital herpes and HSV-1 typically causes orolabial herpes, the prevalence of genital HSV-1 in adolescents has increased significantly [17, 18] . Previously, only about 20% of genital herpes cases were thought to be caused by HSV-1. However, a 2012 HSV vaccine trial indicated that approximately 60% of genital herpes cases in the United States are now caused by HSV-1, with a higher percentage among younger populations [19] . The increase may be the result of the decreasing prevalence orolabial HSV-1 in adolescents and, thus, a lack of HSV-1 antibodies upon sexual debut [20] . It may also be because of increasingly common oral sex practices among adolescents [21] .
CT and NG rates are consistently highest in the southern United States, whereas syphilis rates are highest in the western United States. A map of CT prevalence among adolescent women can be seen in Fig. 2 . CT, NG, and syphilis prevalence is also higher among Black, Hispanic, American Indian, and Pacific Islander populations [2] . Geographic and racial differences in STI prevalence reflect higher levels of poverty and decreased access to and utilization of sexual health services [22] .
YMSM are at an increased risk for STIs due to risk behaviors such as number of partners, concurrent partners, sex with older partners and frequency of sex without a condom [2] . With a syphilis rate of 309 cases/100 000 population, MSM represent over 58% of primary and secondary syphilis cases in the United States (Fig. 3) [23] . As syphilis rates are highest among young men aged 20-24, YMSM are at particularly high risk of syphilis infection [2] . YMSM are also at increased risk for CT and NG infections, specifically antibiotic-resistant NG. The burden of STIs is Sexually transmitted infections in adolescents Shannon and Klausner higher among HIV-infected YMSM than among HIV-uninfected YMSM [24] .
Homeless, incarcerated, and drug-using youth represent additional high-risk populations. A recent review found STIs among homeless adolescents to be associated with length of homelessness, coercive sex, and unmet survival needs [25] . Adolescent drug use and incarceration are also associated with higher rates of STIs due to a combination of behavioral risk factors and unequal access to the healthcare system [26, 27] [32] . Furthermore, for adolescents who are on their parents' insurance plans, concerns about confidentiality breaches through insurance billing are common. According to the 2015 National Survey of Family Growth, 12.7% of sexually experienced adolescents covered by their parent's insurance plan reported they would forgo sexual health services because of concern that their parents would find out. That proportion was higher, 22.6%, among adolescents age 15-17 years [33 && ]. Others reported foregoing screening because they felt they were not at risk for STIs [31 & ]. Confidentiality concerns are important to address when working with adolescents. Adolescent women who had time alone with a provider were more than twice as likely to receive STI screening than those whose parents were in the room, suggesting the value of private discussions between adolescents and their providers [33 && ]. Other options, such as self-collected swabs or home-based specimen collection and testing, may also reduce confidentiality concerns among adolescents and should be further evaluated [34] .
SEXUALLY TRANSMITTED INFECTION MANAGEMENT
STIs in adolescents should be managed according to CDC recommendations [1] . There are no unique recommendations for STI treatment in youth specifically, other than adherence counseling. Research into the effectiveness of STI treatment in adolescent populations is needed.
The CDC recommends treating both urogenital and extragenital CT infections with 1 g oral azithromycin. However, over the past few years, there has been critical appraisal of the effectiveness of treating rectal CT with azithromycin versus doxycycline. Numerous studies have shown doxycycline to be more effective than azithromycin [35] [36] [37] . A retrospective cohort study of rectal CT infection found that azithromycin treatment was associated with a five-fold higher risk of persistent/recurrent infection 14-90 days after treatment when compared with treatment with doxycycline [38] failure is more likely in patients with a higher organism load [39] . Although European guidelines recommend treating oral and rectal CT infections with doxycycline, the CDC has not yet updated recommendations [1, 40] . Large, randomized controlled trials are urgently needed. An emerging challenge in the management of STIs is the shortage of penicillin benzathine G, both in the United States and globally. Penicillin benzathine G is the recommended treatment for syphilis, and the only recommended syphilis treatment option for pregnant women [1] . Although syphilis rates are at their highest in 20 years, penicillin benzathine G has become unavailable in many hospitals [41] . In Japan, amoxicillin has been successfully used as an alternative to penicillin benzathine G to treat syphilis infection and prevent mother-tochild transmission [42 & ,43] . The rise of antibiotic-resistant NG and even untreatable NG is another important issue in the management of STIs. In 2016, the Gonococcal Isolate Surveillance Project reported that 44.1% of NG isolates were resistant to penicillin, tetracycline, and/or ciprofloxacin [2, 44] . Furthermore, the past decade has shown an increase in isolates with an elevated minimal inhibitory concentration to the cephalosporins cefixime and ceftriaxone [45] . There have also been reports of treatment failures to cefixime and ceftriaxone [46, 47] . Owing to the emergence of resistance, two-drug therapy is now recommended, utilizing both 1 g azithromycin and 250 mg injectable ceftriaxone. There are no data on the rates of resistance in adolescent populations specifically, but the two-drug treatment recommendations apply regardless of age or anatomical site of infection [1] .
Partner notification and treatment is another essential aspect of STI management. In adolescent populations, this can be particularly challenging because of the higher frequency of concurrent partners and relationships of shorter duration. However, high rates of STI reinfection among youth indicate the critical importance of partner management [48] . Expedited partner therapy, where the patient delivers medication or a prescription to the partner, has been shown to be a successful option to treat CT or NG infection in heterosexual adult couples. Data are limited regarding the effectiveness of expedited partner therapy in adolescents or MSM. Expedited partner therapy is recommended for MSM in most states, although not universally [2, 49] .
PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS
The WHO has made STI prevention one of its priorities for 2016-2021 [50] . Prevention efforts are particularly important in adolescents, as sexual health habits are often still developing. Adolescent STI prevention efforts should come from a combination of sources. Traditional sources of information, such as parents and schools, play an important role. Sexual communication between adolescents and their parents has been shown to lead to safer sex behavior [51 & ]. HPV vaccination is also a critical component of adolescent sexual health. It is recommended that both boys and girls age 11-12 years receive the vaccine series. The vaccine is recommended through age 26 years for women, MSM, and HIV-infected patients, and through age 21 for heterosexual men [1] . The vaccine is well tolerated and highly effective in preventing most HPV infections [52, 53] .
There is also potential for powerful prevention efforts via social media. Social media campaigns are an effective way to communicate prevention messages to specific, targeted audiences [54] . Numerous campaigns promoting STI testing and safe sex practices have been shown to increase STI testing and safer sex behavior [55] [56] [57] . As mobile dating apps become more popular, especially among adolescents, they represent a unique venue through which to reach adolescents at high risk for STIs. A recent study found that it was feasible to use Grindr (West Hollywood, United States), a dating app for MSM, to distribute HIV self-testing kits [58] . It would be valuable to evaluate a similar model for home-based STI testing.
FUTURE DIRECTIONS
Preexposure vaccines are the most powerful method for infection prevention. With vaccination rates around 51% for adolescent women aged 14-19 years, the HPV vaccine has led to a substantial reduction in HPV types 6, 11, 16, and 18 [2] . However, broader coverage through HPV vaccination requirements represents the potential for a further significant decrease in HPV-related cancer and associated costs. Rhode Island, Virginia, and Washington DC require HPV vaccination for school entry [59] .
Effective vaccines for other STIs would significantly improve sexual health. Vaccine development efforts vary by specific STI. HSV and CT vaccine candidates are in clinical trials, whereas NG and syphilis vaccine candidates are still in preclinical development [60 & ,61] . Notably, a recent study showed a serogroup B meningococcal vaccine to be 31% effective against NG, the first instance of a protective vaccine against NG [62 && ,63]. Meanwhile, a TV vaccine development program will require a better fundamental understanding of the TV Sexually transmitted infections in adolescents Shannon and Klausner parasite and the epidemiology of the infection [60 & ]. STI vaccines represent a worthy research investment because of the high burden of STIs and the increasing challenges posed by antibiotic resistance. A 2016 study indicated high acceptance of a CT vaccine among adolescents [64] .
Rapid point-of-care diagnostic testing represents another exciting development in the field of STIs. Numerous rapid diagnostic tests for common STIs such as CT and NG are in development or newly on the market [65] . Rapid point-of-care testing creates a large potential for improved management, as patients could be screened and treated in the same day, reducing loss to follow-up [66] . Furthermore, rapid STI testing efforts could be integrated into the current infrastructure for rapid HIV testing, increasing access to testing and treatment of STIs. The advent of rapid diagnostic tests has important implications globally as well. In the majority of low and middle-income countries, STIs such as CT and NG are managed through symptom-based management because of the high cost of testing [50] . However, symptom-based management leads to a large number of untreated infections because of the often asymptomatic nature of STIs. Furthermore, it likely leads to unnecessary antibiotic treatment. As new rapid diagnostic tests become available, evaluations will be needed to demonstrate the cost-effectiveness of point-of-care STI testing in the global setting.
CONCLUSION
STIs are a common cause of disease in adolescents. As STI rates in the United States rise, it is critical to understand and address the epidemic from both medical and public health perspectives. Prevention efforts, ranging from HPV vaccination to social media awareness campaigns, are important to confront the epidemic from a population perspective. Meanwhile, provider-based screening and timely patient and partner treatment are essential to improve adolescent clinical care. Moving forward, research is needed to determine optimal strategies to increase adoption of routine screening among adolescents, particularly among high-risk populations such as young women and YMSM. 
